Influx Healthtech IPO Allotment: A Step-By-Step Guide To Check Status Online Today, Know Latest GMP

Last Updated:
According to market observers, the GMP of the Influx Healthtech IPO is 22.92%, indicating decent listing gains for investors.
Influx Healthtech IPO Allotment: The initial public offering of Influx Healthtech has received a whopping 201.35 times subscription, indicating huge interest from investors. Investors are now eagerly awaiting its allotment even its latest GMP shows a strong 22.92% listing gains. The allotment of the Influx Healthtech IPO is expected to be finalised today, Monday, June 23, in the evening.
Once the IPO allotment is finalised, investors will start receiving bank debit messages, most probably in the evening. They can also check their allotment status on the websites of the NSE as well as registrar Maashitla Securities Private Limited.
The allotment is expected to be finalised in the evening today, Friday, June 20. The allotment status can be checked by following these steps:
Step 1: Visit Maashitla Securities' portal — https://maashitla.com/allotment-status/public-issues.
Step 2: Under 'Select Company', choose 'Influx Healthtech Ltd'. Importantly, if the company's name is not visible in the drop-down list, it means the allotment has not been finalised yet.
According to market observers, the GMP of the Influx Healthtech IPO is 22.92%, indicating decent listing gains for investors.
The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price.
Influx Healthtech IPO Listing Date
The shares of Influx Healthtech Ltd will be listed on the NSE Emerge on June 25.
The Influx Healthtech IPO was open for subscription between June 18 and June 20. It is a book-built issue worth Rs 58.57 crore, comprising a fresh issue of 50 lakh equity shares worth Rs 48 crore and an offer for sale of 11 lakh shares aggregating to Rs 10.56 crore.
On the final day of bidding on Friday, the SME IPO received an overwhelming 201.35 times subscription, garnering bids for 81,71,71,200 shares as against 40,58,400 shares on offer. The retail and NII participation stood at 117.68 times and 481.10 times, respectively. Its qualified institutional buyer (QIB) category got a 137.87 times subscription.
The price of the Influx Healthtech IPO was fixed at Rs 96 apiece.
Influx Healthtech Ltd's revenue increased 5% and its profit after tax (PAT) rose 19% between the financial year ending with March 31, 2025, and March 31, 2024.
Rarever Financial Advisors Pvt Ltd is the book-running lead manager of the Influx Healthtech IPO, while Maashitla Securities Private Limited is the registrar for the issue. The market maker for Influx Healthtech IPO is R K Stock Holding Private Limited.
Influx Healthtech Ltd, founded in September 2020, is a healthcare-focused CDMO with three manufacturing units in Thane, producing tablets, capsules, powders, liquid orals, and softgels.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

United News of India

32 minutes ago

• United News of India

Sampre Nutritions Ltd Plans Strategic Fundraising Initiative to Drive Growth and Expansion

New Delhi [India], June 21: Sampre Nutritions Ltd (BSE: 530617), a leading confectionery manufacturer, has proposed fund raising initiative through various modes such as preferential issue. Communicated earlier this year to BSE, the company is likely to hold Board of Directors meeting in near future, for the shareholders to consider and approve plans for raising funds via issuance of eligible securities. The proposed capital raise may involve issuance of eligible securities of the company, in one or more ways, through public and/or private offerings, including by way of preferential issue, qualified institutions placement and / or further public offering, subject to such approvals as may be required, including approval of the shareholders of the Company. The aim is to strengthen the company's financial structure and support its ongoing expansion and diversification efforts. The management of the company commented 'This is an important step in our journey as we explore ways to expand operations, extend market penetration, and invest in long-term growth. The fundraising initiative highlights our commitment towards building a stronger, more resilient future at Sampre Nutritions Limited' As part of the process, the Board will also consider convening an Extraordinary General Meeting (EGM) or initiating a postal ballot to seek shareholder approval. Earlier in April 2024, the company successfully allotted 17 lakh equity shares at Rs 36 each following the conversion of warrants issued on a preferential basis. On October 14, 2024, the Board approved the conversion of 85 Foreign Currency Convertible Bonds (FCCBs), originally allotted on June 28, 2024, into equity shares. This resulted in the allotment of 1,19,42,116 fully paid-up equity shares of face value of Rs 10 at a conversion price of Rs 59.84 per share, increasing the company's paid-up capital to Rs. 2.09 crore comprising of 20,91,212 equity shares of face value of Rs. 10 each. Subsequently, in October 2024, the company received in-principle approval from BSE for listing of 89,91,711 equity shares of face value of Rs 10 each at a price of Rs 59.84 per equity share. Along with this, the company also received approval for issuance of 10,00,000 warrants convertible into equity shares of face value of Rs 10 each at a price of Rs 60.50 per equity share on a preferential basis. In November 2024, the company approved the allotment of 8,40,000 warrants on a preferential basis to non-promoters at a price of Rs 60.50 per warrant, each convertible into one equity share of face value Rs 10. The company was also awarded the Certificate of Recognition under the India 5000 Best MSME Awards 2024 for excellence in quality, customer satisfaction, and societal impact. The company recently announced its Q4 FY25 and FY25 consolidated financial result. The consolidated revenue from operations remained stable at Rs 25.12 crore. The company reported a consolidated net loss of Rs 7.67 crore, mainly on account of investment into subsidiaries and higher finance costs. For Q4 FY25, company reported revenue of Rs 7.76 crore, a growth from Rs 4.76 crores reported in Q4 FY24. About Sampre Nutritions Ltd: Incorporated in 1991 and headquartered in Medchal, Telangana, Sampre Nutritions Ltd is engaged in manufacturing complete range of confectionery, éclairs, candies, lollipops, toffees, powder and centre filled products. The company is instrumental to deliver the growing volumes for most of the MNC's and beside producing its own brand. The group is one stop shop for complete range of confectionary productions. It has multiple MNC's as their clients as Mondelez India Pvt Ltd, Perfetti Van Melle, Reliance, DS Group, Nestle to name a few… The promoter is also the President for Indian Confectionery Manufacturers Association and is into the industry for the past 4 decades Sampre Nutrition is the first ISO certified company in South East Asia in this category since 1995 and is the 1st HACCP Certified Company by BVQI and FSSA Version 6 certified company with receiving Multiple Quality Awards World Wide. Further the company is associated with Mondelez India Pvt Ltd for manufacturing Eclairs for the past 30 Years and the Sole Manufacturer for Eclairs for the past 8 years for India, China and South African Market.

Time of India

33 minutes ago

• Time of India

Coimbatore gets additional district consumer commission

COIMBATORE: Coimbatore has got an additional district consumer disputes redressal commission to ensure speedy disposal of pending cases at the principal district commission. Tired of too many ads? go ad free now As many as 58 cases have been transferred to the newly established additional commission so far. An official source said all pending cases from 2023 and 2024, which are ready for arguments at the principal district commission, were allocated to the additional commission for disposal. The additional commission began functioning on June 16. It is functioning from Room No 7 on the first floor of the old building on the collectorate campus. It will function three days a week—from Monday to Wednesday. However, sources noted that the additional commission lacks adequate space and is currently operating from a single room, making it difficult for the staff to maintain records or even find space to sit. Every year, around 500 new cases are filed at the principal district commission. At present, approximately 350 cases are pending before it. 'District commissions shall have jurisdiction to entertain complaints where the value of goods or services paid as consideration does not exceed Rs 50 lakh. The Consumer Protection Act, 2019, stipulates that every complaint shall be disposed of as expeditiously as possible, and an endeavour shall be made to decide the complaint within three months from the date of receipt of notice by the opposite party,' the source added.

Business Standard

35 minutes ago

• Business Standard

Northern Arc Capital rallies after Madhusudan Kela's fund picks stake

Shares of Northern Arc Capital rose 11% to Rs 230.40 after ace investor Madhusudan Kela's fund Cohesion MK Best Ideas Sub-Trust acquired shares of the firm via block deals on 20 June 2025. On 20 June 2025, Kela's fund, Cohesion MK Best Ideas Sub-Trust, acquired 10 lakh shares (0.62% equity) of Northern Arc at Rs 208.83 each, according to bulk deal data disclosed by the exchanges. Meanwhile, BNP Paribas Financial Markets acquired 8,67,328 shares, or a 0.54% stake, in the company at Rs 202.46 per share. In a separate transaction, asset manager 360 ONE exited a 12.02% stake in Northern Arc Capital through open market deals on June 20. The firm, via three affiliated funds -- Series 4, Series 5, and Series 7 -- sold 1.94 crore shares at prices between Rs 195.71 and Rs 198.74, amounting to a total deal value of over Rs 382 crore. Northern Arc is a diversified NBFC. It offers a suite of solutions including lending, placements, and fund investments in key sectors like MSME financing, MFI, consumer financing, vehicle financing, affordable housing financing, and agricultural supply chain finance. Northern Arc handles an AUM of Rs 16,792 crore through its balance sheet and active AIF funds as of 31 March 2025. On a consolidated basis, net profit of Northern ARC Capital declined 57.48% to Rs 37.76 crore while total income rose 7.42% to Rs 606.72 crore in Q4 March 2025 over Q4 March 2024.